Visual analysis of global research on immunotherapy for gastric cancer: A literature mining from 2012 to 2022

ABSTRACT Gastric cancer (GC) is one of the most common malignancies. Immunotherapy becomes an indispensable part of GC. This study conducts bibliometric analysis of immunotherapy for GC to clarify the research status and identify potential new research directions. VOS viewer and CiteSpace visualization software were used to demonstrate collaborations and correlations. A total of 1141 English publications from 2012 to 2022 were included. The number of publications increased year by year. The publications were mainly from China (n = 579, 50.70%), followed by the United States. Fudan University published the most publications (n = 48, 4.21%). Frontiers in Oncology and Journal of Clinical Oncology ranked first in cited and co-cited journals, respectively. Kim Kyoung-Mee published the most publications on immunotherapy for GC (n = 14). The clustering of timeline view and co-cited references show the hotspot transformation on immunotherapy for GC. Initially, the hot topic was “cytokine-induced killer cells” and “myeloid-derived suppressor cells.” In recent years, the focus has turned to “targeted therapy.” “CAR-T” has become the hottest topic, and GC has entered precision therapy phase. Screening patients who can benefit from immunotherapy is key to improving prognosis. The combination of immunotherapy with other treatment options, such as chemotherapy and targeted therapy, is currently the focus of research. Chimeric antigen receptor T cell will be further studied in the future.

[1]  H. Kagamu.  Current Status of Immune Checkpoint Inhibitors , 2022, Nihon Kikan Shokudoka Gakkai Kaiho.

[2]  Mo-pei Wang,et al.  Advances in molecular biomarkers research and clinical application progress for gastric cancer immunotherapy , 2022, Biomarker research.

[3]  Xiaotian Zhang,et al.  Predicting response to immunotherapy in gastric cancer via multi-dimensional analyses of the tumour immune microenvironment , 2022, Nature Communications.

[4]  K. Yin,et al.  Recent Progress and Future Perspectives of Immunotherapy in Advanced Gastric Cancer , 2022, Frontiers in immunology.

[5]  Xia Li,et al.  Research progress in targeted therapy and immunotherapy for gastric cancer , 2022, Chinese medical journal.

[6]  Zonghai Li,et al.  Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results , 2022, Nature Medicine.

[7]  Zhi-Chun Gu,et al.  Antimicrobial Stewardship in Surgery: A Literature Bibliometric Analysis , 2022, Frontiers in Public Health.

[8]  Xiaotian Zhang,et al.  Plasma extracellular vesicle derived protein profile predicting and monitoring immunotherapeutic outcomes of gastric cancer , 2022, Journal of extracellular vesicles.

[9]  Weiguang Yang,et al.  Knowledge structure and emerging trends on osteonecrosis of the femoral head: a bibliometric and visualized study , 2022, Journal of Orthopaedic Surgery and Research.

[10]  Elnaz Faghfuri,et al.  Cellular immunotherapy in gastric cancer: adoptive cell therapy and dendritic cell-based vaccination. , 2022, Immunotherapy.

[11]  Zhongqi Li,et al.  Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study , 2022, Journal for ImmunoTherapy of Cancer.

[12]  Zhi Peng,et al.  Efficacy and predictive biomarkers of immunotherapy in Epstein-Barr virus-associated gastric cancer , 2022, Journal for ImmunoTherapy of Cancer.

[13]  Quan P. Ly,et al.  Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. , 2022, Journal of the National Comprehensive Cancer Network : JNCCN.

[14]  Lixin Ke,et al.  Knowledge Mapping of Immunotherapy for Hepatocellular Carcinoma: A Bibliometric Study , 2022, Frontiers in Immunology.

[15]  A. Jemal,et al.  Cancer statistics, 2022 , 2022, CA: a cancer journal for clinicians.

[16]  E. Van Cutsem,et al.  The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer , 2021, Nature.

[17]  Meiqin Wu,et al.  Studies on Children With Developmental Coordination Disorder in the Past 20 Years: A Bibliometric Analysis via CiteSpace , 2021, Frontiers in Psychiatry.

[18]  Luxia Song,et al.  A Bibliometric Analysis of Pyroptosis From 2001 to 2021 , 2021, Frontiers in Immunology.

[19]  Lianmei Zhao,et al.  Advances in clinical immunotherapy for gastric cancer. , 2021, Biochimica et biophysica acta. Reviews on cancer.

[20]  Qing‐Yu He,et al.  Targeted Immunotherapies in Gastrointestinal Cancer: From Molecular Mechanisms to Implications , 2021, Frontiers in Immunology.

[21]  Kyoung-Mee Kim,et al.  Tumor microenvironment evaluation promotes precise checkpoint immunotherapy of advanced gastric cancer , 2021, Journal for ImmunoTherapy of Cancer.

[22]  Ka Li,et al.  Emerging trends and focus of human gastrointestinal microbiome research from 2010–2021: a visualized study , 2021, Journal of Translational Medicine.

[23]  Fenghua Wang,et al.  The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021 , 2021, Cancer communications.

[24]  J. Ajani,et al.  First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial , 2021, The Lancet.

[25]  W. Park,et al.  Determinants of Response and Intrinsic Resistance to PD-1 Blockade in Microsatellite Instability-High Gastric Cancer. , 2021, Cancer discovery.

[26]  M. Sampson,et al.  Bibliometric Analysis of Neurology Articles Published in General Medicine Journals , 2021, JAMA network open.

[27]  Rosalie M Sterner,et al.  CAR-T cell therapy: current limitations and potential strategies , 2021, Blood Cancer Journal.

[28]  P. Sharma,et al.  The Next Decade of Immune Checkpoint Therapy. , 2021, Cancer discovery.

[29]  Y. Bang,et al.  Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials. , 2021, JAMA oncology.

[30]  T. Yoshikawa,et al.  Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab , 2021, Gastric Cancer.

[31]  Wanqing Chen,et al.  Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020 , 2021, Chinese medical journal.

[32]  Qian Zhang,et al.  The antitumor capacity of mesothelin-CAR-T cells in targeting solid tumors in mice , 2021, Molecular therapy oncolytics.

[33]  Xiaoling Lu,et al.  A CTLA-4 blocking strategy based on Nanoboby in dendritic cell-stimulated cytokine-induced killer cells enhances their anti-tumor effects , 2021, BMC cancer.

[34]  B. Xing,et al.  Development of a model to predict pathologic response to chemotherapy in patients with colorectal liver metastases. , 2021, Journal of gastrointestinal oncology.

[35]  Xianguo Li,et al.  Fractal structures arising from interfacial instabilities in bio-oil atomization , 2021, Scientific reports.

[36]  Y. Bang,et al.  Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100 , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  Y. Bang,et al.  First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811 , 2020, Future oncology.

[38]  Linli Zheng,et al.  Epilepsy Occurrence and Circadian Rhythm: A Bibliometrics Study and Visualization Analysis via CiteSpace , 2020, Frontiers in Neurology.

[39]  J. George,et al.  Comprehensive Molecular Characterization of Adenocarcinoma of the Gastroesophageal Junction Between Esophageal and Gastric Adenocarcinomas , 2020, Annals of surgery.

[40]  Runliang Gan,et al.  Epstein-Barr virus-associated gastric cancer: A distinct subtype. , 2020, Cancer letters.

[41]  L. Shen,et al.  Safety and efficacy of sintilimab combined with oxaliplatin/capecitabine as first-line treatment in patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in a phase Ib clinical trial , 2020, BMC Cancer.

[42]  H. Grabsch,et al.  Gastric cancer , 2020, The Lancet.

[43]  T. Kanda,et al.  Cross-species chromatin interactions drive transcriptional rewiring in Epstein–Barr virus–positive gastric adenocarcinoma , 2020, Nature Genetics.

[44]  K. Koike,et al.  Tumor microenvironment in gastric cancers , 2020, Cancer science.

[45]  C. la Vecchia,et al.  Effectiveness and Healthcare Cost of Adding Trastuzumab to Standard Chemotherapy for First-Line Treatment of Metastatic Gastric Cancer: A Population-Based Cohort Study , 2020, Cancers.

[46]  S. Nakajima,et al.  Current status of immune checkpoint inhibitors for gastric cancer , 2020, Gastric Cancer.

[47]  B. Taylor,et al.  First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial. , 2020, The Lancet. Oncology.

[48]  Wanqing Chen,et al.  Cancer burden of major cancers in China: A need for sustainable actions , 2020, Cancer communications.

[49]  S. Nomura,et al.  Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603). , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  Ling Wei,et al.  Noncoding RNAs in gastric cancer: implications for drug resistance , 2020, Molecular Cancer.

[51]  Morwenna Rogers,et al.  Resources for forwards citation searching for implementation studies in dementia care: A case study comparing Web of Science and Scopus , 2020, Research synthesis methods.

[52]  A. Agarwal,et al.  Unraveling the Footsteps of Proteomics in Male Reproductive Research: A Scientometric Approach. , 2019, Antioxidants & redox signaling.

[53]  Liming Yao,et al.  Freshwater microplastics pollution: Detecting and visualizing emerging trends based on Citespace II. , 2019, Chemosphere.

[54]  M. Sauer,et al.  A Bibliometric Analysis of Top-Cited Journal Articles in Obstetrics and Gynecology , 2019, JAMA network open.

[55]  Yi Sui,et al.  Knowledge domain and emerging trends in Alzheimer’s disease: a scientometric review based on CiteSpace analysis , 2019, Neural regeneration research.

[56]  T. Yamanaka,et al.  Multicenter phase I/II study of nivolumab combined with paclitaxel plus ramucirumab as the second-line treatment in patients with advanced gastric cancer. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[57]  Y. Jiang,et al.  Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432 , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[58]  Jakob Nikolas Kather,et al.  Deep learning can predict microsatellite instability directly from histology in gastrointestinal cancer , 2019, Nature Medicine.

[59]  Ligang Xia,et al.  The roles of extracellular vesicles in gastric cancer development, microenvironment, anti-cancer drug resistance, and therapy , 2019, Molecular Cancer.

[60]  Lei Tang,et al.  The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer , 2019, Cancer communications.

[61]  Y. Liao,et al.  Tumor Microenvironment Characterization in Gastric Cancer Identifies Prognostic and Immunotherapeutically Relevant Gene Signatures , 2019, Cancer Immunology Research.

[62]  Zhen-Chang Wang,et al.  A scientometric analysis on hepatocellular carcinoma magnetic resonance imaging research from 2008 to 2017. , 2019, Quantitative imaging in medicine and surgery.

[63]  Suna Wang,et al.  Mesothelin is a target of chimeric antigen receptor T cells for treating gastric cancer , 2019, Journal of Hematology & Oncology.

[64]  B. Shi,et al.  Claudin18.2-Specific Chimeric Antigen Receptor Engineered T Cells for the Treatment of Gastric Cancer. , 2018, Journal of the National Cancer Institute.

[65]  Y. Bang,et al.  Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study , 2019, Gastric Cancer.

[66]  X. Yi,et al.  Autologous Dendritic Cell-Cytokine Induced Killer Cell Immunotherapy Combined with S-1 Plus Cisplatin in Patients with Advanced Gastric Cancer: A Prospective Study , 2018, Clinical Cancer Research.

[67]  Joon-Oh Park,et al.  Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer , 2018, Nature Medicine.

[68]  Kazuhiro Yoshida,et al.  Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial , 2018, The Lancet.

[69]  S. Pyo,et al.  Folate receptor 1 (FOLR1) targeted chimeric antigen receptor (CAR) T cells for the treatment of gastric cancer , 2018, PloS one.

[70]  Beibei Yan,et al.  The hotspots of life cycle assessment for bioenergy: A review by social network analysis. , 2018, The Science of the total environment.

[71]  P. Philip,et al.  Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial , 2018, JAMA oncology.

[72]  A. Veillette,et al.  SIRPα-CD47 Immune Checkpoint Blockade in Anticancer Therapy. , 2018, Trends in immunology.

[73]  G. Bhanot,et al.  Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer. , 2018, Journal of the National Cancer Institute.

[74]  Juan Li,et al.  Antitumor effects and persistence of a novel HER2 CAR T cells directed to gastric cancer in preclinical models. , 2018, American journal of cancer research.

[75]  T. Yoshikawa,et al.  Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial , 2017, The Lancet.

[76]  Fengjun Xiao,et al.  Knowledge Domain and Emerging Trends in Organic Photovoltaic Technology: A Scientometric Review Based on CiteSpace Analysis , 2017, Front. Chem..

[77]  H. Bae,et al.  Clinical significance of tumor-infiltrating lymphocytes for gastric cancer in the era of immunology , 2017, World journal of gastrointestinal oncology.

[78]  J. Utikal,et al.  Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer , 2017, Nature.

[79]  H. Xi,et al.  Phase II Trial of Adjuvant Immunotherapy with Autologous Tumor-derived Gp96 Vaccination in Patients with Gastric Cancer , 2017, Journal of Cancer.

[80]  G. Fasola,et al.  Immunotherapy for gastric cancers: emerging role and future perspectives , 2017, Expert review of clinical pharmacology.

[81]  R. Hagedoorn,et al.  TCR-based therapy for multiple myeloma and other B-cell malignancies targeting intracellular transcription factor BOB1. , 2017, Blood.

[82]  Jie Ding,et al.  Effectiveness and safety of chemotherapy combined with cytokine-induced killer cell /dendritic cell-cytokine-induced killer cell therapy for treatment of gastric cancer in China: A systematic review and meta-analysis. , 2016, Cytotherapy.

[83]  Y. Chu,et al.  Bifunctional αHER2/CD3 RNA-engineered CART-like human T cells specifically eliminate HER2+ gastric cancer , 2016, Cell Research.

[84]  J. Lunceford,et al.  Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. , 2016, The Lancet. Oncology.

[85]  W. Lewis,et al.  The 100 most influential manuscripts in gastric cancer: A bibliometric analysis. , 2016, International journal of surgery.

[86]  Ying Cheng,et al.  Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial , 2016, BMC Cancer.

[87]  Lin Chen,et al.  Interleukin‐15‐transferred cytokine‐induced killer cells elevated anti‐tumor activity in a gastric tumor‐bearing nude mice model , 2016, Cell biology international.

[88]  K. Ogawa,et al.  The efficacy of adjuvant immunochemotherapy with OK-432 after curative resection of gastric cancer: an individual patient data meta-analysis of randomized controlled trials , 2016, Gastric Cancer.

[89]  B. Vogelstein,et al.  PD-1 blockade in tumors with mismatch repair deficiency. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[90]  P. Sharma,et al.  Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential , 2015, Cell.

[91]  G. Wang,et al.  Prolonged overall survival in gastric cancer patients after adoptive immunotherapy. , 2015, World journal of gastroenterology.

[92]  K. Kinzler,et al.  The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints , 2015, Journal of Immunotherapy for Cancer.

[93]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of gastric adenocarcinoma , 2014, Nature.

[94]  Y. Doki,et al.  Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1) , 2014, British Journal of Cancer.

[95]  S. Steinberg,et al.  Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy , 2011, Clinical Cancer Research.

[96]  Yoon-Koo Kang,et al.  Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial , 2010, The Lancet.